Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal CancerScott Kopetz, Josep Tabernero, Neeltje Steeghs et al.|New England Journal of Medicine|2019Cited by 1.5k
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b studyLecia V. Sequist, Geoffrey R. Oxnard, Ji‐Youn Han et al.|The Lancet Oncology|2020Cited by 413
Modified Low Density Lipoprotein Stimulates Complement C3 Expression and Secretion via Liver X Receptor and Toll-like Receptor 4 Activation in Human MacrophagesDenis A. Mogilenko, Sergey Orlov|Journal of Biological Chemistry|2011Cited by 59
Multiarm, nonrandomized, open-label phase IB study to evaluate FP1039/GSK3052230 with chemotherapy in NSCLC and MPM with deregulated FGF pathway signaling.Pilar Garrido, Ulrik Lassen, Enriqueta Felip et al.|Journal of Clinical Oncology|2014Cited by 4
Multi-Arm, Nonrandomized, Open-Label Phase Ib Study to Evaluate Fp1039/Gsk3052230 with Chemotherapy in Nsclc and Mpm with Deregulated Fgf Pathway SignalingPilar Garrido, Ulrik Lassen, Enriqueta Felip et al.|Annals of Oncology|2014Cited by 3